{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:57:33Z","timestamp":1776329853211,"version":"3.50.1"},"reference-count":19,"publisher":"Baskent University","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.6002\/ect.2025.0132","type":"journal-issue","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:22:16Z","timestamp":1773051736000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Baran W, Krzemi\u0144ska J, Szlagor M, et al. Mineralocorticoid receptor antagonist: use in chronic kidney disease. Int J Mol Sci. 2021;22(18):9995. doi:10.3390\/ijms22189995","DOI":"10.3390\/ijms22189995"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Erraez S, L\u00f3pez-Mesa M, G\u00f3mez-Fern\u00e1ndez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021;41(3):258-275. doi:10.1016\/j.nefro.2020.10.001","DOI":"10.1016\/j.nefro.2020.10.001"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9(8):459-469. doi:10.1038\/nrneph.2013.110","DOI":"10.1038\/nrneph.2013.110"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Lahmer T, Hermans R, Schmaderer C, et al. Mineralocorticoid receptor antagonism and aldosterone synthesis inhibition do not improve glomerulosclerosis and renal interstitial fibrosis in a model of chronic kidney allograft injury. Kidney Blood Press Res. 2012;35(6):561-567. doi:10.1159\/000339649","DOI":"10.1159\/000339649"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Chung EY, Ruospo M, Natale P, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020;10(10):CD007004. doi:10.1002\/14651858.CD007004.pub4","DOI":"10.1002\/14651858.CD007004.pub4"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Dong D, Fan TT, Ji YS, Yu JY, Wu S, Zhang L. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int Urol Nephrol. 2019;51(4):755-764. doi:10.1007\/s11255-019-02074-9","DOI":"10.1007\/s11255-019-02074-9"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. de Sousa MV, Guida JP, do Valle CF, Camargo LF, Rivelli GG, Mazzali M. Spironolactone in post-transplant proteinuria: a safe alternative therapy. Transplant Proc. 2017;49(4):813-816. doi:10.1016\/j.transproceed.2017.01.075","DOI":"10.1016\/j.transproceed.2017.01.075"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Mortensen LA, Jespersen B, Helligsoe ASL, et al. Effect of spironolactone on kidney function in kidney transplant recipients (the SPIREN trial): a randomized placebo-controlled clinical trial. Clin J Am Soc Nephrol. 2024;19(6):755-766. doi:10.2215\/CJN.0000000000000439","DOI":"10.2215\/CJN.0000000000000439"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326\/0003-4819-150-9-200905050-00006","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003;3 Suppl 4:114-125. doi:10.1034\/j.1600-6143.3.s4.11.x","DOI":"10.1034\/j.1600-6143.3.s4.11.x"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Haas M, Sis B, Racusen LC, et al.; Banff meeting report writing committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272-283. doi:10.1111\/ajt.12590","DOI":"10.1111\/ajt.12590"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Ponticelli C, Graziani G. Proteinuria after kidney transplantation. Transpl Int. 2012;25(9):909-917. doi:10.1111\/j.1432-2277.2012.01500.x","DOI":"10.1111\/j.1432-2277.2012.01500.x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Afsar B, Afsar RE, Caliskan Y, Lentine KL. Mineralocorticoid receptor blockage in kidney transplantation: too much of a good thing or not? Int Urol Nephrol. 2025;57(3):839-854. doi:10.1007\/s11255-024-04256-6","DOI":"10.1007\/s11255-024-04256-6"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Leader CJ, Kelly DJ, Sammut IA, Wilkins GT, Walker RJ. Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat. Physiol Rep. 2020;8(10):e14448. doi:10.14814\/phy2.14448","DOI":"10.14814\/phy2.14448"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Barrera-Chimal J, P\u00e9rez-Villalva R, Rodr\u00edguez-Romo R, et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int. 2013;83(1):93-103. doi:10.1038\/ki.2012.352","DOI":"10.1038\/ki.2012.352"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Dibo P, Mareddy NSR, Kojima GSA, et al. Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. BMC Nephrol. 2025;26(1):438. doi:10.1186\/s12882-025-04161-9","DOI":"10.1186\/s12882-025-04161-9"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Medeiros M, Vel\u00e1squez-Jones L, Hern\u00e1ndez AM, et al. Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy. Clin J Am Soc Nephrol. 2017;12(8):1291-1300. doi:10.2215\/CJN.05300516","DOI":"10.2215\/CJN.05300516"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Baskin E, Siddiqui MA, G\u00fcllero\u011flu K, et al. Long\u2010term effect of eplerenone treatment in children with chronic allograft nephropathy. Pediatr Transplant. 2023;27(6):e14557. doi:10.1111\/petr.14557","DOI":"10.1111\/petr.14557"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Zhai S, Ma B, Chen W, Zhao Q. A comprehensive review of finerenone: a third-generation non-steroidal mineralocorticoid receptor antagonist. Front Cardiovasc Med. 2024;11:1476029. doi:10.3389\/fcvm.2024.1476029","DOI":"10.3389\/fcvm.2024.1476029"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T10:45:26Z","timestamp":1773053126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2026\/24\/2\/0\/111\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2025.0132","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}